Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy

Samah Gadhoum; Nour Yaseen Rabah Madhoun; Ayman AbuElela; Jasmeen Merzaban

doi:10.1038/leu.2016.221

Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy

Samah Gadhoum, Nour Yaseen Rabah Madhoun, Ayman AbuElela, Jasmeen Merzaban

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	2397-2401
Number of pages	5
Journal	Leukemia
Volume	30
Issue number	12
DOIs	https://doi.org/10.1038/leu.2016.221
State	Published - Aug 8 2016

Bibliographical note

KAUST Repository Item: Exported on 2020-10-01
Acknowledgements: This work was supported by the King Abdullah University of Science and Technology (KAUST) faculty baseline research funding program to JSM.

Access to Document

10.1038/leu.2016.221

https://repository.kaust.edu.sa/bitstream/10754/620939/1/10.1038-leu.2016.221.pdf

Cite this

@article{7cdcafaa3fcf4b71bcb16e74337e7d2a,

title = "Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy",

author = "Samah Gadhoum and Madhoun, {Nour Yaseen Rabah} and Ayman AbuElela and Jasmeen Merzaban",

note = "KAUST Repository Item: Exported on 2020-10-01 Acknowledgements: This work was supported by the King Abdullah University of Science and Technology (KAUST) faculty baseline research funding program to JSM.",

year = "2016",

month = aug,

day = "8",

doi = "10.1038/leu.2016.221",

language = "English (US)",

volume = "30",

pages = "2397--2401",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "12",

}

TY - JOUR

T1 - Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy

AU - Gadhoum, Samah

AU - Madhoun, Nour Yaseen Rabah

AU - AbuElela, Ayman

AU - Merzaban, Jasmeen

N1 - KAUST Repository Item: Exported on 2020-10-01 Acknowledgements: This work was supported by the King Abdullah University of Science and Technology (KAUST) faculty baseline research funding program to JSM.

PY - 2016/8/8

Y1 - 2016/8/8

UR - http://hdl.handle.net/10754/620939

UR - http://www.nature.com/leu/journal/vaop/ncurrent/full/leu2016221a.html

UR - http://www.scopus.com/inward/record.url?scp=84987677244&partnerID=8YFLogxK

U2 - 10.1038/leu.2016.221

DO - 10.1038/leu.2016.221

M3 - Article

C2 - 27499140

SN - 0887-6924

VL - 30

SP - 2397

EP - 2401

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy

Bibliographical note

Access to Document

Other files and links

Cite this